Richard Clark, MD
Internal Medicine · Jamestown, TNNPI 1962406793
Payments from drug & device makers
Across 231 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$825
- AbbVie$472
- Amgen$335
- Boehringer Ingelheim$315
- AstraZeneca$305
- Bayer$190
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $825 |
| AbbVie(2 entities) | 32 | $472 |
| Amgen | 15 | $335 |
| Boehringer Ingelheim | 22 | $315 |
| AstraZeneca | 20 | $305 |
| Bayer | 12 | $190 |
| Lilly USA, LLC | 12 | $188 |
| Pfizer | 11 | $168 |
| Evoke Pharma, Inc. | 6 | $164 |
| GSK | 9 | $153 |
| Merck | 9 | $153 |
| Hikma Pharmaceuticals USA | 8 | $141 |
| Xeris Pharmaceuticals, Inc. | 5 | $118 |
| Collegium Pharmaceutical, Inc. | 5 | $74 |
| Novartis | 4 | $63 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Exact Sciences | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$3,951 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $54,838 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,508 | $47,786 |
| JardianceEmpagliflozin | 61 | $41,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $40,056 |
| OzempicSemaglutide | 35 | $37,107 |
| Xtampza ErOxycodone Myristate | 69 | $32,800 |
| Oxycodone Hcl | 1,326 | $30,790 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $21,143 |
| RybelsusSemaglutide | 19 | $19,980 |
| UbrelvyUbrogepant | 15 | $19,287 |
| MounjaroTirzepatide | 16 | $17,164 |
| FarxigaDapagliflozin Propanediol | 23 | $15,675 |
| Gabapentin | 1,301 | $15,601 |
| LinzessLinaclotide | 23 | $14,515 |
| EntrestoSacubitril/Valsartan | 19 | $12,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $315 | $71,286103 claims |
| Novo NordiskOzempic, Rybelsus | $825 | $57,08854 claims |
| PfizerEliquis | $168 | $54,83874 claims |
| GSKTrelegy Ellipta | $153 | $40,05656 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $305 | $34,32768 claims |
| AbbVieUbrelvy, Linzess | $472 | $33,80338 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $74 | $32,80069 claims |
| Lilly USA, LLCMounjaro | $188 | $17,16416 claims |
| NovartisEntresto | $63 | $12,97919 claims |
| MerckJanuvia | $153 | $11,67620 claims |
| BayerKerendia | $190 | $7,98912 claims |
| Hikma Pharmaceuticals USAKloxxado | $141 | $7,12958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Jamestown
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.